Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.

ABSTRACT:

Background

Effective prevention against coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently limited to nonpharmaceutical strategies. Laboratory and observational data suggested that hydroxychloroquine had biological activity against SARS-CoV-2, potentially permitting its use for prevention.

Objective

To test hydroxychloroquine as postexposure prophylaxis for SARS-CoV-2 infection.

Design

Household-randomized, double-blind, controlled trial of hydroxychloroquine postexposure prophylaxis. (ClinicalTrials.gov: NCT04328961).

Setting

National U.S. multicenter study.

Participants

Close contacts recently exposed (<96 hours) to persons with diagnosed SARS-CoV-2 infection.

Intervention

Hy

SUBMITTER: Barnabas RV 

PROVIDER: S-EPMC7732017 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature